Irish biotechnology company Elan rejected on Monday the latest takeover bid from US group Royalty Pharma worth about $7.9 billion (6.0 billion euros).
"Elan Corporation plc today announced that its board of directors ... has rejected the revised bid from privately held investment firm Royalty Pharma," it said in a statement.
"The value gap between the underlying value of Elan plc and the totality of its business platform and the Royalty Pharma/Echo bid remains significant," it added.
On Friday, Royalty Pharma had tabled an offer worth up to $15.50 per Elan share, made up of $13.00 in cash and up to $2.50 depending on the performance of its blockbuster multiple-sclerosis drug Tysabri.
Elan had sold its half of Tysabri in February to US development partner Biogen Idec Inc. for $3.25 billion. The Dublin-based company has retained a royalty stream from sales of the drug.
Royalty's third takeover offer compared with the previous bid of $12.50 per share in cash, worth $6.4 billion. Elan has repeatedly rejected Royalty's approaches.
- Dow Jones Newswires contributed ti this report -
Explore further: Judge halts Royalty Pharma's bid for Elan stock